A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions

The purpose of this Study is to assess the safety and effectiveness of treating blockages in the coronary (heart) arteries (blood vessels) with an investigational (experimental) device called Absorb™ Bioresorbable Vascular Scaffold (BVS) System (the “Absorb BVS”), compared to a commercially approved metallic stent coated with medication (drug-eluting stent).
Heart & Vascular - Interventional Cardiology Trials
Robert Bersin, MD
Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, post-infarct angina or silent ischemia) suitable for elective PCI. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
Inger Rasmussen